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Abstract 
This study reports on the encapsulation efficiency of proteins in dextran sulfate / poly-L-arginine based 
microcapsules, fabricated via Layer-by-Layer assembly (LbL). For this purpose, radiolabeled proteins 
are entrapped in CaCO3 microparticles followed by LbL coating of the CaCO3 cores and subsequent 
dissolving of the CaCO3 using EDTA. To allow to improve protein encapsulation in LbL microcapsules, 
we studied all steps in the preparation of the microcapsules where loss of protein load might occur. The 
encapsulation efficiency of proteins in LbL microcapsules turns out to be strongly dependent on both the 
charge and molecular weight of the protein as well as on the number of polyelectrolyte bilayers the 
microcapsules consist of.  
 2 
Keywords: microcapsules, protein delivery, calcium carbonate, Layer-by-Layer, microparticles 
 
Introduction 
Nano- and microparticles, made from a plethora of materials, are currently widely investigated as drug 
carriers. Since a couple of years, a number of groups became interested in so named polyelectrolyte 
capsules as drug carriers. Such capsules are fabricated by the Layer-by-Layer (LbL) technique based on 
the consecutive adsorption of oppositely charged polymers on colloidal cores used as sacrificial 
templates.1 Subsequent core removal gives rise to “hollow” capsules ranging in size from nanometers to 
micrometers according to the sacrificial template used.2,3 Such polyelectrolyte capsules are built up of a 
polymer wall and have an inner cavity which may be loaded with various types of (therapeutic) 
molecules; literature reports on loading of the LbL capsules with various cargo molecules including low 
molecular weight drugs,4 polymers,5 enzymes,6-8 DNA9  and protein antigens.3  
The properties of polyelectrolyte capsules can be tuned by proper selection of the shell constituents 
and the core template used in the fabrication.10 The shell can be customized, as a variety of polymers can 
serve as building materials: going from synthetic polymers1,11 over biodegradable polymers.12-14 The 
majority of polyelectrolyte capsules reported today are composed of synthetic polymers, mainly the 
anionic poly(sodium)styrenesulfonate and the cationic poly(allylamine)hydrochloride. However, for 
pharmaceutical and biological settings, use of biocompatible and biodegradable materials (vulnerable to 
e.g. enzymatic degradation) is required.15,16 As an example, our group encapsulated antigen proteins in 
polyelectrolyte microcapsules consisting of dextran sulfate and poly-L-arginine; we showed that such 
capsules degrade in dendritic cells through proteases and subsequently release the antigen.3,17 Besides 
tuning the permeability of the capsule shell by variations in shell thickness, the capsule surface can also 
be functionalized by e.g. poly(ethylene glycol),18 lipids,19 antibodies,20 dyes21 and nanoparticles.22,23  
Two strategies have been envisaged for the encapsulation of substances in LbL capsules. In a first 
(“post-loading”) approach, preformed capsules are loaded with molecules by temporarily manipulating 
the permeability of the capsule shell by changes in pH,24,25 ionic strength12 or solvent polarity7 of the 
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dispersion. In the second approach, the substances of interest are already entrapped in the sacrificial 
template before the onset of the LbL coating and are thus present at the moment of core removal. It is 
clear that, depending on the type of drug to be loaded into the capsules, a proper selection of the 
sacrificial core is of outermost importance as both core removal and loading of preformed microcapsules 
often occur under rather extreme conditions (like changes in ionic strength or use of organic or highly 
acidic/alkaline solvents), which may have a negative impact on the biological activity of e.g. protein 
drugs. A variety of colloidal substrates has been used such as cross-linked melamine formaldehyde 
(MF),1 polystyrene,25 SiO2,26 and carbonate (MnCO3, CdCO3, CaCO3) particles.27,28 These templates can 
be dissolved respectively by hydrochloric acid (HCl), tetrahydrofuran (THF), hydrogenfluoride (HF) 
and ethylene diamine tetraacetic acid (EDTA).  
The use of CaCO3 particles as decomposable templates offers interesting prospects to encapsulate 
proteins in polyelectrolyte capsules under mild conditions; indeed, the protein molecules can be 
coprecipitated at the moment of the CaCO3 core formation and after deposition of the multilayered shell, 
the core can be dissolved by Ca2+ complexation with an aqueous EDTA solution involving minimal 
stress for the encapsulated proteins.28 Understanding which parameters fundamentally influence the 
encapsulation efficiency of proteins in LbL microcapsules and whether protein loading of the capsules is 
well reproducible are basic requirements to judge whether LbL microcapsules will ever have a chance to 
become pharmaceutically used as protein carriers. Therefore, in the current study we aimed to 
investigate the encapsulation efficiency of proteins in dextran sulfate / poly-L-arginine microcapsules 
templated on CaCO3 cores, which we took as a model for biodegradable LbL microcapsules. We set out 
to elucidate how both the protein and microcapsule characteristics influence the encapsulation 
efficiency. Especially, we aimed at identifying which steps in the preparation of protein loaded LbL 
microcapsules most crucially determine the loading of polyelectrolyte microcapsules with proteins.  
 
Materials and Methods 
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1. Materials. Albumin from human serum (HSA, 67 kDa, IEP 4,7), -lactalbumin (14 kDa, IEP 4,3), 
ethylenediamine-tetraacetic acid disodium salt (EDTA),  IgG from bovine serum (150 kDa), calcium 
chloride (CaCl2), sodium carbonate (Na2CO3), dextran sulfate sodium salt (Mw ~ 10 kDa), poly-L-
arginine hydrochloride (Mw > 70 kDa) and rhodamine isothiocyanate (RITC) were purchased from 
Sigma-Aldrich-Fluka. All materials were used without further purification. RITC labeled poly-L-
arginine was prepared by mixing poly-L-arginine and RITC 25:1 in 0.1 M borate buffer pH 8.5. Reaction 
was allowed overnight, residual RITC was removed by dialysis of the mixture against water using 
Spectra Por dialysis membrane. Lysozyme (14 kDa, IEP 11,1) was obtained from Fédération 
International Pharmaceutique (FIP). 
 Micro BCA Protein Assay Kit, Coomassie (Bradford) Protein Assay Kit and Pierce pre-coated 
iodination tubes were obtained from Thermo Scientific. Phosphate buffered saline (PBS) was purchased 
from Invitrogen. [99mTc] Human Serum Albumin and [111In] Ig G (ProstaSint®) were purchased from 
Mallinckrodt Medical and EUSA Pharma respectively. [131I] was obtained from Perkin Elmer.  
2. Preparation of (protein loaded) calcium carbonate microparticles. CaCO3 particles were 
prepared by mixing an equal volume of a Na2CO3 (1.0 M) and a CaCl2 (1.0 M) solution under stirring,27 
followed by washing with water. In order to obtain calcium carbonate particles loaded with protein, 
100 µl, 500 µl or 1000 µl of a 1 mg/ml solution of respectively lysozyme, -lactalbumin, HSA or IgG 
was added to the CaCl2 solution prior to mixing with the Na2CO3 solution. In this way protein molecules 
became entrapped within growing (precipitating) CaCO3 particles. 
3. Preparation of hollow multilayer microcapsules. Polyelectrolyte microcapsules consisting of 
biodegradable dextran sulfate and poly-L-arginine were prepared by applying the LbL technique on the 
CaCO3 particles, as illustrated in Figure 1. Briefly, the CaCO3 particles were dispersed in a 2 mg/ml 
dextran sulfate solution containing 0.5 M NaCl. After adsorption of the polyelectrolyte, the 
microparticles were collected by centrifugation for 3 minutes at 300 g. Subsequently, particles were 
washed twice with distilled water to remove excess dextran sulfate. In the next step, microparticles were 
incubated in a 1 mg/ml poly-L-arginine solution in 0.5 M NaCl, followed by centrifugation and washing 
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again. This LbL procedure was repeated until the desired number of bilayers was deposited. Removing 
the CaCO3 cores, by dispersing the LbL coated cores in a 0.2 M EDTA solution, gave rise to hollow 
polyelectrolyte microcapsules. 
4. Characterization of polyelectrolyte microcapsules:  Confocal laser scanning microscopy 
(CLSM). Confocal microscopy images of RITC labeled dextran sulfate / poly-L-arginine microcapsules 
were recorded using a Nikon C1si confocal laser scanning module attached to a motorized Nikon 
TE2000-E inverted microscope. Therefore a drop of microcapsule suspension was placed on a cover 
glass and analyzed with CLSM using a water immersion objective lens (Plan Apo 60X, NA 1.2, collar 
rim correction, Nikon). 
5. Scanning electron microscopy (SEM). For scanning electron microscopy images, samples were 
prepared by dropping CaCO3 microparticles or LbL microcapsule suspension onto a silicon wafer, air 
dried and sputtered with gold. Observations were performed using a  Quanta 200 FEG FEI scanning 
electron microscope operated at 5 kV. 
6. Zetapotential measurement. The zetapotential of the microparticles was determined at each 
adsorption step in the LbL procedure with a Zetasizer nano series (Malvern). Therefore, the 
microparticles were dispersed in distilled water; the reported zetapotential value is the average of three 
consecutive measurements. The CaCO3 cores exhibited a zetapotential of +6 mV ± 1,8 mV. 
Coprecipitation of -lactalbumin, HSA, IgG or lysozyme with the CaCO3 cores resulted in zetapotential 
values of -11,2 mV ± 2,8 mV, -15,1 mV ± 2,9 mV, -10,9 mV ± 2,0 mV and +8,7 mV± 0,9 mV, 
respectively. 
7. Determination of encapsulation efficiency through spectrophotometric measurements. To 
determine the protein encapsulation efficiency in the CaCO3 particles, after the precipitation reaction the 
CaCO3 particles were centrifuged and the supernatans containing the non encapsulated protein was 
collected. Then, particles were washed twice with distilled water and washing waters were kept aside. 
For each concentration, particles were prepared in triplicate. The amount of protein in the supernatans 
and wash fractions was quantified spectrophotometrically by BCA and Bradford assays (described 
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below). The protein encapsulation efficiency (EE) in the calcium carbonate particles was calculated 
using the following equation: 
 
EE% =                                                                 x100% 
 
BCA protein determination: The Micro BCA assay kit (Pierce) was used for protein quantification. 
Protein standards of lysozyme, -lactalbumin, HSA or IgG (containing 0-25 µg of the protein per ml 
distilled water) were prepared. To each standard and unknown sample an equal volume of the BCA 
working reagent was added. Following mixing, samples were incubated at 37°C for 2 hours. After 
cooling to room temperature, the absorbance of the samples was measured at 562 nm (Shimadzu UV 
1800). A linear relationship was observed between the concentration of the protein standards and the 
absorbance. 
Coomassie (Bradford) protein determination: Supernatans and washing waters were collected and 
assayed spectrophotometrically at 595nm (Shimadzu UV 1800) with Bradford’s protein assay method 
(n=3).29 For standard curves, dilution series of lysozyme,-lactalbumin, HSA or IgG were prepared in 
the concentration range of 0-25 µg protein per ml distilled water. 
8. Determination of encapsulation efficiency through radioactivity measurements:  
Radiolabeling of lysozyme and -lactalbumin. Lysozyme and -lactalbumin were labelled with 
[131I] using Pierce pre-coated iodination tubes (IODO-GEN). Na131I in PBS was added to the Pierce 
iodination tube and subsequently protein solution in PBS was added. Reaction was allowed to proceed 
for 15 minutes at room temperature. Afterwards, iodide was removed from the iodinated protein by gel 
filtration (on a PD-10 column using CaCl2 as mobile phase) and instant thin-layer chromatography 
(ITLC) was used to determine radiochemical purity. 
9. Direct measurement by using radiolabeled proteins. Radiolabeled model proteins of varying 
molecular weight were used for encapsulation in the microcapsules (following the procedure described 
above), namely [131I] –lactalbumin (14 kDa), [131I] lysozyme (14 kDa), [99mTc] Human Serum Albumin 
(total protein – free protein in supernatans) 
total protein 
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(HSA, 67 kDa) and [111In] IgG (150 kDa). All samples were made in triplicate. Aliquots of the washings, 
coating solutions, EDTA solution and the polyelectrolyte microcapsules dispersion were counted for 
radioactivity by a NaI(Tl) gamma scintillation counter (Packard Instruments) in order to investigate 
protein loss throughout the LbL procedure and to determine the final encapsulation efficiency in the 
microcapsules. The results were corrected for decay, and radioactivity concentrations are expressed as 
the percentage of the total radioactivity measured (mean ± standard deviation values, n=3). 
 
Results and discussion 
1. Characterization of hollow polyelectrolyte microcapsules templated on CaCO3 cores 
After mixing the CaCl2 and Na2CO3 solutions, the resulting CaCO3 microparticles (displaying a 
narrow size distribution (2-4 µm); data not shown) were coated with bilayers of dextran sulfate and 
poly-L-arginine, as schematically illustrated in Figure 1. 
 
 
Figure 1. Schematic representation of the preparation of protein filled polyelectrolyte microcapsules. 
(A) During calcium carbonate core formation the protein is coprecipitated, (B) followed by deposition 
of a first polyelectrolyte layer (i.e. dextran sulfate in this study) and (C) deposition of a second layer of 
an oppositively charged polyelectrolyte (i.e. poly-L-arginine in this study). (D) Consecutive LbL coating 
with dextran sulfate / poly-L-arginine until the desired number of bilayers is reached. (E) Finally, 
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hollow microcapsules loaded with proteins are obtained by dissolution of the calcium carbonate core 
with EDTA.  
The stepwise polyelectrolyte adsorption on the surface of the (porous) CaCO3 microparticles (SEM 
image in Figure 2B) was monitored by measuring the electrophoretic mobility after deposition of each 
polyelectrolyte layer (Figure 2A). Before LbL coating, the CaCO3 microparticles exhibited a 
zetapotential of +6 mV while it switched between -25 mV and +21 mV during the LbL procedure 
indicating the binding of respectively polyanions and polycations. When the desired number of 
polyelectrolyte bilayers was reached, hollow microcapsules were obtained by immersing the coated 
microparticles in an EDTA solution to dissolve the CaCO3 cores. In Figure 2C one can see such hollow 
LbL microcapsules in a collapsed state due to the drying of the sample before SEM imaging. Figure 2D 
shows a confocal microscopy image of hollow microcapsules which were fluorescently labeled by 
adsorption of one layer of RITC  poly-L-arginine. 
 
Figure 2. (A) Zetapotential measurements of CaCO3 particles sequentially coated by dextran sulfate and 
poly-L-arginine layers. The x-axis indicates the layer number: 0 corresponds to uncoated CaCO3 
particles, 1 and 3 correspond to dextran sulfate deposition while 2 and 4 are steps in which poly-L-
arginine was deposited. The zetapotential alters between positive and negative values indicating 
deposition of respectively polyanions and polycations. (B) SEM images of CaCO3 microparticle (before 
LbL coating) and (C) hollow polyelectrolyte microcapsules after CaCO3 removal using EDTA. (D) 
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Confocal image showing polyelectrolyte microcapsules consisting of 2 bilayers dextran sulfate / poly-L-
arginine; the microcapsules are fluorescently labeled by incorporation of RITC poly-L-arginine. 
2. Encapsulation efficiency of proteins in the CaCO3 cores 
In a first approach the loading of proteins in the CaCO3 particles was determined by measuring the 
amount of protein which was not entrapped, so named ‘indirect measurements’ in the continuation of 
this paper. The reason why we followed this indirect approach was the fact that, though protein 
molecules could be easily released out of the CaCO3 cores by dissolving them with EDTA, the protein 
concentration could not be determined through BCA and Bradford assays as EDTA interferes in these 
assays. The protein encapsulation efficiency of CaCO3 cores was studied for three negatively charged 
proteins with varying molecular weights, namely -lactalbumin 14 kDa, HSA 67 kDa and IgG 150 kDa. 
On top we also investigated the effect of the protein’s iso-electric-point (IEP) on the encapsulation 
efficiency. Therefore, we tested lysozyme (14 kDa) as a model protein that is positively charged under 
the conditions the proteins become entrapped in the growing CaCO3 particles.  
  100 µg* 500 µg* 1 mg* 
BCA -lactalbumin 95.31 ± 0.55 94.91 ± 0.60 94.80 ± 0.54 
 Lysozyme 0.54 ± 0.44 0.72 ± 1.10 0.58 ± 0.90 
 HSA 92.70 ± 0.65 91.88 ± 0.89 92.53 ± 0.44 
 IgG 92.10 ± 1.62 92.75 ± 0.18 92.90 ± 1.58 
     
Bradford -lactalbumin 95.29 ± 0.91 94.84 ± 0.38 94.90 ± 0.20 
 Lysozyme 0.06 ± 1.58 0.09 ± 0.22 0.09 ± 0.67 
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 HSA 93.02 ± 0.36 93.10 ± 1.75 93.12 ± 0.65 
 IgG 93.48 ± 1.44 93.55 ± 0.84 92.85 ± 0.44 
*
Indicates the amount of protein used in the experiments  
Table 1. Encapsulation efficiency (in %) of proteins in CaCO3 particles, as obtained through BCA or 
Bradford assay (n=3). 
Table 1 shows the results. For the negatively charged proteins -lactalbumin, HSA and IgG, high 
loading efficiencies (i.e. over 90%) were observed; thus both low and high molecular weight negatively 
charged proteins become well entrapped by CaCO3 cores. Also note that, for the protein concentration 
range we tested, the concentration of the protein did not affect the encapsulation efficiency of the 
proteins in the CaCO3 cores. In clear contrast, however, less than 1% of the positively charged lysozyme 
became entrapped in the CaCO3 cores. Apparently, the high IEP of the lysozyme hampered the protein-
CaCO3 interaction leading to a very low amount of protein which becomes finally entrapped.  The exact 
reason for this remains speculative though it is reasonable to assume that electrostatic forces play part in 
the adsorption process. Because both lysozyme and the surface of the CaCO3 particles (Figure 2A) are 
positively charged, electrostatic repulsions may inhibit the loading of the particles with lysozyme. 
Volodkin et al. also noticed that the charge of both the macromolecules (proteins and dextran) and the 
microparticles influence the affinity of the macromolecules to the carbonate surface and thus the 
adsorption on the CaCO3 surface; they showed that electrostatic interactions are playing a major 
contribution in this phenomenon.27 
 In a second approach the protein loading in the CaCO3 particles was determined through 
radioactivity measurements. Therefore, radiolabeled [131I] -lactalbumin, [131I] lysozyme, [99mTc] HSA 
or [111In] IgG were entrapped in CaCO3 particles during the precipitation reaction. To determine the non-
encapsulated fraction, the radioactivity of respectively the supernatans and washing waters was 
measured. Moreover the CaCO3 particles were dissolved in EDTA solution to release the entrapped 
protein and radioactivity was measured. 
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 100 µg* 500 µg* 1 mg* 
[
131
I]-Lactalbumin 95.68 ± 0.26 96.03 ± 0.2 95.68 ± 0.26  
[
131
I]Lysozyme 0.84 ± 0.39 0.87 ± 0.20  0.60 ± 0.20  
[99mTc]HSA 93.66 ± 0.48 94.07 ± 0.80 94.14 ± 0.78  
[
111
In]IgG 90.47 ± 0.77 93.37 ± 0.44 94.57 ± 0.78 
*
Indicates the amount of protein used in the experiments  
Table 2. Encapsulation efficiency (in %) of proteins in CaCO3 particles as obtained through 
radioactivity measurements after dissolution of the cores in EDTA, (n=3).  
As depicted in Table 2 high loadings were obtained with the negatively charged proteins [131I] -
lactalbumin, [99mTc] HSA and [111In] IgG, in good agreement with the results obtained through Bradford 
and BCA assaying. Also, [131I] lysozyme did not coprecipitate with the CaCO3 particles. The results in 
Table 2 suggest that there is no influence of the protein’ s molecular weight but a major influence of its 
charge on the entrapment efficiency in CaCO3 particles. Overall, coprecipitation of (negatively charged) 
proteins and calcium carbonate is an excellent method for achieving high entrapment efficiencies; this is 
attractive as most therapeutically relevant proteins are negatively charged at physiological conditions. 
 
3. Encapsulation efficiency of proteins in LbL microcapsules 
In a next step we were interested to know the encapsulation efficiency of the proteins in the LbL 
microcapsules. The preparation of the LbL microcapsules took off with the entrapment of protein in 
CaCO3 particles by coprecipitation as illustrated in Figure 1, the desired number of polyelectrolyte 
bilayers was deposited on the particles. The preparation came to an end by dissolving the CaCO3 cores 
with EDTA yielding hollow microcapsules containing protein in their aqueous cavity. We aimed (a) to 
determine the (overall) encapsulation efficiency of proteins in the LbL microcapsules and, especially, 
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(b) to identify which steps in the preparation of LbL microcapsules are the most critical in the 
encapsulation process.  
Microcapsules were built up of bilayers of dextran sulfate / poly-L-arginine. To determine the 
encapsulation efficiency of proteins in such LbL microcapsules we could no longer make use of the 
BCA or Bradford assays as the encapsulated proteins could not be released from the microcapsules (due 
to the LbL shell). Though dextran sulfate / poly-L-arginine LbL layers can be degraded upon exposure 
to proteolytic enzymes,3,14 releasing the encapsulated proteins through enzymatic degradation of the 
shells was not an option as the poly-L-arginine present in the LbL layers would interfere in the BCA  
and Bradford assays. We were thus limited to the use of radiolabeled proteins to determine the protein 
encapsulation efficiency in the LbL microcapsules by measuring protein while it is present in the 
microcapsules’ cavity.  
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Table 3. Loss of protein (%) at deposition of the 1st dextran sulfate layer and upon dissolving the CaCO3 
cores using EDTA, and encapsulation efficiency (in %) of proteins in the LbL microcapsules (n=3). 
  
Number  
of bilayers 
1st dextran 
sulfate layer EDTA 
Polyelectrolyte 
microcapsules 
[
131
I]-lactalbumin 100 µg 1 12.36 ±4.60 77.46 ± 6.24 3.91 ± 0.16 
  2  67.74 ± 1.52 8.24 ± 0.46 
  3  56.97 ± 4.75 9.79 ± 0.33 
 1 mg 1 17.17 ± 2.13 72.21 ± 1.02 4.61 ± 0.89 
  2  64.80 ± 0.66 6.98 ± 0.21 
  3  62.32 ± 1.37 6.90 ± 0.14 
      
[99mTc]HSA 100 µg 1 9.95 ± 1.55 70.11 ± 3.63 9.43 ± 1.28 
  2  52.89 ± 4.54 24.04 ± 4.31 
  3  54.51 ± 6.16 23.44 ± 4.17 
 1 mg 1 10.21 ± 1.04 68.73 ± 0.18 12.14 ± 0.17 
  2  53.83 ± 4.16 23.73 ± 1.05 
  3  57.18 ± 3.07 19.01 ± 1.33 
      
[
111
In]IgG 100 µg 1 4.61 ± 0.78 30.06 ± 4.16 57.83 ± 3.50 
  2  12.57 ± 1.76 70.96 ± 1.79 
 
 3  11.58 ± 1.90 69.39 ± 0.47 
     
 1 mg 1 4.31 ± 0.68 30.14 ± 0.27 60.16 ± 1.40 
  2  17.94 ± 1.66 69.22 ± 2.13 
  3  12.65 ± 2.86 72.00 ± 3.53 
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Table 3 shows the results on the encapsulation of [131I] -lactalbumin, [99mTc] HSA and [111In] IgG in 
microcapsules built up of respectively one, two or three bilayers of dextran sulfate / poly-L-arginine. 
Upon applying the first dextran sulfate layer on the CaCO3 cores we observed a partial loss of proteins 
(Table 3), this was also observed for -lactalbumin by others.27 This loss occurred for the different 
proteins, however to a lower extent in the case of the larger 150 kDa IgG; on average 14% of -
lactalbumin, 10% of HSA while only 4% of IgG was released. We hypothesize that upon CaCO3 core 
formation protein molecules do not only become entrapped within the cores, though part of them 
becomes adsorped on the surface of the CaCO3 particles. Likely, the huge number of dextran sulfate 
chains in the “coating solution” compete with the (negatively charged) proteins for surface binding. The 
reason why a lower percentage of the higher molecular weight HSA and IgG seem to be released is 
rather unclear; however, one could argue that the higher the protein’s molecular weight, the higher the 
number of interactions between a protein molecule and a CaCO3 core, the more difficult it might be for 
dextran sulfate chains to “liberate” the surface adsorped proteins. Importantly, we observed that further 
applying polyelectrolyte layers on the dextran sulfate coated CaCO3 cores did no longer cause release of 
proteins (data not shown).  
In a next step, the LbL coated CaCO3 templates were dispersed in EDTA. We observed that in this 
step a ‘rearrangement’ of the polyelectrolyte layers occurs; indeed, after dissolution of the CaCO3 we 
noticed a change in zetapotential (data not shown; in agreement with previous observations30). Upon 
dissolving the CaCO3 we noticed a spectacular loss of proteins from the microcapsules: all data are 
overviewed in Table 3 and Figures 3 and 4. 
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Figure 3. Loss of protein from microcapsules, composed of different number of dextran sulfate / poly-
L-arginine bilayers, upon dissolution of the CaCO3 cores with EDTA, (1 mg of protein was used in the 
experiments, n=3). 
 
Figure 4. Encapsulation efficiency (in %) of proteins in LbL microcapsules, (1 mg of protein was 
used in the experiments, n=3). 
 
We observed that for-lactalbumin on average 75% of the initial protein amount was set free upon 
dissolving cores of so named “one bilayer microcapsules” (which  are CaCO3 particles coated with one 
bilayer). When the CaCO3 were coated with respectively two and three bilayers, less-lactalbumin 
became released. In case of HSA, “one bilayer microcapsules” lost around 70% of the protein compared 
to 55% for the two and three bilayered microcapsules. For IgG, one bilayer microcapsules released 30%, 
only 14% of IgG became lost for the two and three bilayered capsules.  
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Clearly, loss of protein upon dissolution of the CaCO3 is thus dependent on the number of bilayers 
which coat the CaCO3. The more bilayers, the less permeable the LbL shell, the lower the loss of 
protein.31 Especially, when comparing one and two bilayered microcapules in case of all modelproteins 
a striking difference in protein loss catches the eye: decreasing release with increasing number of 
bilayers. However comparing the two and three bilayered microcapsules, we observed that for the low 
molecular weight protein -lactalbumin the release at core dissolution is still decreasing with increasing 
bilayer number, whereas for the higher molecular weight proteins HSA and IgG, there are no significant 
differences in protein release observed indicating that the number of bilayers is not the only factor 
determining the final encapsulation efficiency in LbL capsules. One could suggest that the loss of 
protein could be even more lowered by further increasing the number of bilayers, which is of course 
true. Though, for drug delivery purposes a lower number of bilayers might be desirable. Indeed, it has 
been shown that antigen release kinetics from carriers may impact the immunological outcome;32,33 as a 
consequence, when microcapsules are used to deliver e.g. protein antigen to dendritic cells, the 
microcapsules should become degraded over a relatively short time so that the antigen is set free for 
degradation and subsequent presentation of the antigenic peptides on MHC molecules by the dendritic 
cell. 
The effect of the protein’s molecular weight on the encapsulation efficiency in LbL microcapsules 
was further investigated. As shown in Table 3 and Figures 3 and 4, the higher the molecular weight of 
the protein the lower the loss upon dissolving the CaCO3 of the LbL microcapsules. This phenomenon is 
reasonable to expect and can obviously be explained by a more limited diffusion of larger molecules 
through the LbL shell. 
 
Conclusions 
 Understanding which parameters fundamentally influence the encapsulation efficiency of proteins in 
LbL microcapsules is crucial information for the further development of LbL microcapsules as protein 
carriers in pharmacy. Therefore, to get insight in this matter, and, especially, to be able to optimize 
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protein encapsulation in LbL microcapsules, we studied all steps in the preparation of microcapsules 
where loss of protein load might occur. Our experiments revealed a high entrapment efficiency (>90%) 
of negatively charged proteins in CaCO3 microparticles; this appeared to be extremely dependent on the 
IEP of the protein: positively charged lysozyme became (nearly completely) excluded from CaCO3 
microparticles.  
 Applying dextran sulfate as first polyelectrolyte layer on the protein loaded CaCO3 cores resulted in 
loss of protein which we attributed to displacement of surface adsorped protein in favour of dextran 
sulfate; the higher the molecular weight of the protein the lower the amount of protein which was lost. 
Deposition of additional polyelectrolyte layers did not result in a further loss of proteins. By far the most 
critical step turned out to be the dissolution of the CaCO3 cores of the LbL microcapsules. We showed 
that the extent of protein loss at this critical step was dependent on (i) the protein’s molecular weight 
and (ii) the number of bilayers the microcapsules were comprised of. LbL microcapsules consisting of 
several polyelectrolyte bilayers kept the proteins better as their shell is less permeable. Especially, 
compared to lower molecular weight proteins, higher molecular weight proteins seemed to be much 
better retained by the capsules upon dissolving the calcium carbonate cores.  
Our data show that major differences exist in the encapsulation efficiency of proteins in LbL 
microcapsules, with values ranging from 4% to over 70%. It was demonstrated that for-lactalbumin 
the one bilayer microcapsules retained on average only 4% of the initial protein amount, the two and 
three bilayer microcapsules kept about 7-9%. In case of HSA, one bilayer microcapsules withhold 9 to 
12% of the protein compared to 19 to 24% for the two and three bilayer microcapsules. For IgG the 
encapsulation efficiencies started at 58% for the one bilayer microcapsules and even rised above 70% 
for the two and three bilayer microcapsules. We believe that this quantitative information should be 
taken into account in all further studies in which protein loaded LbL microcapsules will be investigated 
with respect to one or another objective. 
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